32 min listen
What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans
What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans
ratings:
Length:
12 minutes
Released:
Aug 8, 2017
Format:
Podcast episode
Description
Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the global giant’s plans for additional Dry Eye treatments may be.
Released:
Aug 8, 2017
Format:
Podcast episode
Titles in the series (100)
How Thoughtful Consolidation Can Benefit Ophthalmology by OIS Podcast | Ophthalmology's leading Podcast